Drug
Taselisib clinical trials
Also written GDC-0032 and RO5537381.
- studies test it
- 13
- open now
- 0
- in phase 3
- 1
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2013 (4)
| Year | Studies |
|---|---|
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 7
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 7
Genentech, Inc. (5) · National Cancer Institute (NCI) (2) · Royal Marsden NHS Foundation Trust (1) · The Netherlands Cancer Institute (1) · SWOG Cancer Research Network (1) · Centre Hospitalier Universitaire Dijon (1) · Vanderbilt-Ingram Cancer Center (1) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
Palbociclib (2) · Adavosertib (1) · Afatinib (1) · Binimetinib (1) · Capivasertib (1) · Copanlisib (1) · Copanlisib hydrochloride (1) · Crizotinib (1)
Studies
Open first, then newest update. How each study uses taselisib is read from its arms, and is right about nine times in ten.
Testing it · 13
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Taselisib
- Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439175Written as Taselisib
- Trial of Taselisib in OvergrowthTerminatedPhase 1/2Centre Hospitalier Universitaire DijonNCT03290092Written as Taselisib (GDC0032)
- PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibCompletedPhase 1Royal Marsden NHS Foundation TrustNCT02389842Written as Palbociclib + Taselisib / Pictilisib
- Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside TamoxifenCompletedPhase 1/2The Netherlands Cancer InstituteNCT02285179Written as GDC-0032
- Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerTerminatedPhase 1/2Vanderbilt-Ingram Cancer CenterNCT02457910Written as Taselisib
- A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor TherapyTerminatedPhase 3Hoffmann-La RocheNCT02340221Written as Taselisib
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesCompletedPhase 2SWOG Cancer Research NetworkNCT02785913Written as Taselisib
- A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)CompletedPhase 2Genentech, Inc.NCT02273973Written as Taselisib
- A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung CancerCompletedPhase 1Genentech, Inc.NCT01862081Written as GDC-0032
- A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy VolunteersCompletedPhase 1Genentech, Inc.NCT01980953Written as GDC-0032 Phase III Tablet
- A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy VolunteersCompletedPhase 1Genentech, Inc.NCT01967966Written as GDC-0032
- A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy VolunteersCompletedPhase 1Genentech, Inc.NCT01814709Written as GDC-0032
Given in every arm · 2 — taselisib is usual care beside what is tested
- Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast CancerCompletedPhase 1Nancy Lin, MDNCT02390427Written as Taselisib
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerTerminatedPhase 1Genentech, Inc.NCT01296555Written as GDC-0032
Codes
What other systems call taselisib · ClinicalTrials.gg INT006331
- UNII (FDA) L08J2O299MTASELISIBConfirmed FDA, Wikidata
- Wikidata Q27088940taselisibConfirmed FDA, Wikidata
- NCI Thesaurus C116876TaselisibOne source FDA
- DrugBank DB12108One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L08J2O299M | TASELISIB | Confirmed FDA, Wikidata |
| Wikidata | Q27088940 | taselisib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C116876 | Taselisib | One source FDA |
| DrugBank | DB12108 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.